Thomas Cooper
@thomascooper7.bsky.social
Learning is not attained by chance, it must be sought for with ardor and attended to with diligence. Advocate, Crypto , Life Coach, Philanthropist. 🏳️🌈
||Bot|| 👎🏻
||Bot|| 👎🏻
Reposted by Thomas Cooper
the scariest words you'll hear from a voter: "I do my own research" cc: @radiofreetom.bsky.social
December 17, 2024 at 7:38 PM
the scariest words you'll hear from a voter: "I do my own research" cc: @radiofreetom.bsky.social
Reposted by Thomas Cooper
My son challenged me to name all 50 states this morning. I wrote 49/50 pretty quickly—got stuck on the last one for awhile. Want to guess what it was?
December 18, 2024 at 2:19 PM
My son challenged me to name all 50 states this morning. I wrote 49/50 pretty quickly—got stuck on the last one for awhile. Want to guess what it was?
Reposted by Thomas Cooper
So many drones tonight. Including one with the exact coordinates of Jupiter. Someone needs to answer for this.
December 18, 2024 at 3:27 AM
So many drones tonight. Including one with the exact coordinates of Jupiter. Someone needs to answer for this.
Reposted by Thomas Cooper
Goldman Sachs analysts : The money men saying the quiet part out loud
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
www.cnbc.com
December 18, 2024 at 10:48 AM
Goldman Sachs analysts : The money men saying the quiet part out loud
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...